NightHawk Biosciences Provides First Quarter 2022 Business Update May 16, 2022 04:44PM
NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35 May 10, 2022 08:00AM
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today May 3, 2022 07:00AM
Heat Biologics's (HTBX) Elusys Therapeutics Executes a Contract to Deliver ANTHIM to the Canadian Government Apr 27, 2022 08:01AM
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government Apr 27, 2022 08:00AM
View Older Stories

Apr 20, 2022 08:00AM Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
Apr 19, 2022 11:00AM Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
Apr 18, 2022 04:00PM REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
Apr 18, 2022 08:30AM Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
Apr 14, 2022 12:35PM Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
Mar 25, 2022 08:02AM Heat Biologics (HTBX) Unveils Enhanced Allogeneic Cell Manufacturing Process
Mar 25, 2022 08:00AM Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
Mar 23, 2022 08:30AM Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
Mar 14, 2022 08:07AM Heat Biologics (HTBX) Issues Business Update
Mar 14, 2022 08:00AM Heat Biologics Provides Year-End 2021 Business Update
Jan 12, 2022 08:02AM Heat Biologics (HTBX) Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110
Jan 12, 2022 08:00AM Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110
Dec 21, 2021 07:31AM Heat Biologics (HTBX) Announces Planned Acquisition of Elusys Therapeutics
Dec 21, 2021 07:30AM Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
Nov 30, 2021 07:32AM Heat Biologics (HTBX) Announces RapidVax, Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats
Nov 30, 2021 07:30AM Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats
Nov 10, 2021 04:05PM Heat Biologics Provides Third Quarter 2021 Business Update
Oct 6, 2021 07:31AM Heat Biologics (HTBX) Appoints Paul Tebbey as Senior VP of Product Development and Portfolio Strategy
Oct 6, 2021 07:30AM Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
Sep 15, 2021 07:30AM Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
Sep 15, 2021 07:30AM Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
Sep 9, 2021 08:30AM Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 9, 2021 08:30AM Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 30, 2021 07:30AM Heat Biologics to Provide Corporate Update
Aug 26, 2021 08:00AM Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
Aug 23, 2021 08:00AM Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
Aug 19, 2021 09:00AM Heat Biologics Announces New Additions to Biothreat Advisory Board
Aug 18, 2021 08:00AM Heat Biologics Announces Formation of Biothreat Advisory Board
Aug 11, 2021 04:05PM Heat Biologics Provides Second Quarter 2021 Business Update
Aug 9, 2021 07:30AM Heat Biologics Announces Groundbreaking for New San Antonio Facility
Jun 23, 2021 07:34AM Heat Biologics (HTBX) Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
Jun 23, 2021 07:30AM Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
May 5, 2021 07:30AM Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs
Feb 9, 2021 07:32AM Heat Biologics (HTBX) Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial
Feb 9, 2021 07:30AM Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial
Jan 27, 2021 07:30AM Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results
Jan 19, 2021 07:30AM Heat Biologics Commences Manufacturing Process for ZVX-60
Jan 11, 2021 08:08AM Heat Biologics (HTBX) Promotes William L. Ostrander to CFO
Jan 11, 2021 08:00AM Heat Biologics Promotes William L. Ostrander to Chief Financial Officer
Dec 16, 2020 07:32AM Heat Biologics (HTBX) Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19
Dec 16, 2020 07:30AM Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19
Nov 9, 2020 07:00AM Heat Biologics Provides Third Quarter 2020 Business Update
Oct 7, 2020 07:34AM Heat Biologics (HTBX) Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator
Oct 7, 2020 07:30AM Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator
Sep 9, 2020 07:30AM Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th
Sep 2, 2020 07:35AM Heat Biologics (HTBX) Issued Key Patent on Combination Platform Therapy
Sep 2, 2020 07:30AM Heat Biologics Issued Key Patent on Combination Platform Therapy
Aug 26, 2020 07:35AM Heat Biologics (HTBX) Reports Publication of Preclinical COVID-19 Vaccine Results
Aug 26, 2020 07:30AM Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results
Aug 13, 2020 07:01AM Heat Biologics (HTBX) Announces COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies
View Older Stories